Peptides News and Research

RSS

A revolutionary approach to angiogenesis could make cancer treatment more effective at killing tumours

Dr. Olivier Feron and his team from the University of Louvain Medical School in Brussels have turned the whole concept of targeting tumour blood vessels on its head. Instead of the conventional approach of trying to starve tumour cells of the blood supply they need to grow, they are doing the opposite – opening up the tumour blood supply to allow better access for cancer drugs and more effective radiotherapy.

30 Sep 2004

Biomira and Merck announce fast track status for liposome vaccine

Biomira and Merck KGaA have announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track status to the investigation of BLP25 Liposome Vaccine (L-BLP25) for its proposed use in the treatment of non-small cell lung cancer (NSCLC).

29 Sep 2004

Microfluidics help lab-on-a-chip development skyrocket

Lab-on-a-chip (LOC) development has skyrocketed in the last couple of years due to constant efforts in harnessing microfluidics and µTAS to improve the LOC design and function. The distinct advantages that they bestow on applications are pushing the commercial potential of LOCs.

28 Sep 2004

Elan and Wyeth receive patents for Alzheimer's disease treatments

Elan Corporation and Wyeth Pharmaceuticals have announced that the United States Patent and Trademark Office recently issued Neuralab Limited, a subsidiary of Elan, seven patents for the companies’ joint research on immunotherapeutic approaches to the prevention and treatment of Alzheimer’s disease.

23 Sep 2004

Research may lead to alternatives to antibiotic drugs for treating bacterial diseases

UCLA microbiologists report the discovery of a new class of genetic elements, similar to retroviruses, that operate in bacteria, allowing them to diversify their proteins to bind to a large variety of receptors.

23 Sep 2004

Novel strategy for stimulating the production of utrophin

Researchers at the University of Pennsylvania School of Medicine report a novel strategy for stimulating the production of utrophin – an important muscle protein in young mice – for muscular dystrophy therapy.

21 Sep 2004

Immunoglobulins may help patients with Alzheimer’s

Immunoglobulins which are already being used to treat multiple sclerosis may also be able to help patients with Alzheimer’s. This, at least, is the finding of a pilot study on five patients at the University of Bonn.

20 Sep 2004

Immunoglobulins might be promising treatment for Alzheimer's disease

Intravenous immunoglobulin might offer a promising treatment for Alzheimer's disease, suggests preliminary research in the Journal of Neurology Neurosurgery and Psychiatry.

15 Sep 2004

Scientists crack tooth decay

About half of today’s children have tooth decay, so a new solution that blocks the action of bacteria which attack teeth could bring significant benefits, according to scientists speaking Monday at the Society for General Microbiology’s 155th Meeting at Trinity College Dublin.

7 Sep 2004

Sea snail offers natural healing powers for a range of illnesses from chronic pain to diseases of the brain

A beautiful, but often deadly, snail from the sea has been revealed as a largely untapped source of natural healing powers for a range of illnesses from chronic pain to diseases of the brain.

20 Aug 2004

Self-assembling peptides, a breakthrough with enormous therapeutic potential

In the August 12 issue of the journal Nature, researchers at the University of Pennsylvania detail the creation of a library of small protein-like molecules that can self-assemble to form hollow corkscrew-like pores that could mimic pores seen in living systems.

11 Aug 2004

New service-oriented laboratory focused on bioanalysis and pharmacokinetics

Oregon Health & Science University researchers will more quickly move benchtop discoveries toward drug discoveries with the help of a new, service-oriented laboratory focused on bioanalysis and pharmacokinetics.

11 Aug 2004

Zyomyx issued five new biotech patents

Zyomyx a privately held biotechnology company, has announced that the United States Patent and Trademark Office issued five new patents to the Company. With these additions, Zyomyx has further strengthened its proprietary position in the area of protein biochip technology development and commercialization.

6 Aug 2004

A new marker for osteoarthritis

Osteoarthritis (OA) is a common, crippling age-related disease characterized by the gradual destruction of cartilage cushioning the joints.

5 Aug 2004

FDA has granted orphan drug designation to Myogen's ambrisentan, for the treatment of pulmonary arterial hypertension

Myogen has announced that the United States Food and Drug Administration has granted orphan drug designation to ambrisentan for the treatment of pulmonary arterial hypertension (PAH).

3 Aug 2004

Switches in the brain that tell the body to stop eating and start burning calories

A Brown-led research team has discovered a pair of universal switches in the brain that tell the body to stop eating and start burning calories.

3 Aug 2004

Hormone previously identified in the venom of the green mamba snake may play role in stroke research

A Mayo Clinic research team is focusing on a hormone previously identified in the venom of the green mamba snake for the role it may play in a dangerous blood vessel narrowing in stroke patients that can lead to a second stroke, reduced blood flow and brain damage.

2 Aug 2004

New method for detecting premature birth

Researchers at Oregon Health & Science University have discovered a method for detecting intra-amniotic infections in pregnant women using state-of-the-art methods.

29 Jul 2004

Leptin's fat-burning role in humans

For nearly a decade, scientists have known that leptin plays an important fat-burning role in humans. But the map of leptin's path through the body – the key to understanding how and why the hormone works – is still incomplete.

27 Jul 2004

Several key findings from clinical trial of an investigational Alzheimer's disease treatment

Elan Corporation and Wyeth Pharmaceuticals have announced several key findings from their Phase IIa clinical trial of an investigational Alzheimer's disease (AD) treatment, AN-1792, which were presented in Philadelphia at the 9th International Conference on Alzheimer's Disease and Related Disorders.

22 Jul 2004